Docket No. F-8198

## AMENDMENTS TO THE CLAIMS:

Please replace the claims with the claims provided in the listing below wherein status, amendments, additions and cancellations are indicated.

- 1. 3. (Cancelled).
- 4. (Currently Amended) The hyperthermia agent method according to Claim 1 or 2 33, wherein the magnetic fine particles are magnetite.
- 5. (Currently Amended) The hyperthermia agent method according to Claim 4, further comprising covering wherein the magnetite is a magnetite covered by with cationic liposome.
- 6. (Currently Amended) The hyperthermia agent according to Claim 1 or 2 19, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon- $\beta$ , interferon- $\gamma$ , and tumor necrosis factor- $\alpha$ .
  - 7. (Cancelled).

Docket No. F-8198

- 8. (Currently Amended) The hyperthermia agent method according to Claim 4, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon- $\beta$ , interferon- $\gamma$ , and tumor necrosis factor- $\alpha$ .
- 9. (Currently Amended) The hyperthermia agent method according to Claim 6, wherein the cytokine is interleukin-2.
  - 10. (Cancelled).
- 11. (Currently Amended) The hyperthermia agent method according to Claim 8, wherein the cytokine is interleukin-2.
- 12. (Currently Amended) The hyperthermia agent method according to Claim 6, wherein the cytokine is a granulocyte macrophage colony stimulating factor.
  - 13. (Cancelled).

Docket No. F-8198

14. (Currently Amended) The hyperthermia agent method according to Claim 8, wherein the cytokine is a granulocyte macrophage colony stimulating factor.

15. - 18. (Cancelled).

19. (Currently Amended) A method of using cytokine for hyperthermia for treating of a malignant tumor comprising:

administering cytokine to a malignant tumor; and subjecting said tumor to hyperthermia.

20. (Currently Amended) [[A]] The hyperthermia method for treating a of malignant tumor according to claim 19, wherein said malignant tumor is subjected to hyperthermia after said cytokine has been administered to said malignant tumor. which comprises administering cytokine to malignant tumor, then the malignant tumor is subjected to hyperthermia.

21. - 22. (Cancelled).

- 23. (Currently Amended) The hyperthermia agent method according to claim 5, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon- $\beta$ , interferon- $\gamma$ , and tumor necrosis factor- $\alpha$ .
  - 24. 32. (Cancelled).
- 33. (New) A method of using cytokine and hyperthermia for treatment of a malignant tumor according to claim 19, wherein said subjecting said tumor to hyperthermia comprises administering magnetic fine particles to said tumor and heating said magnetic fine particles.
- 34. (New) A method of using cytokine and hyperthermia for treatment of a malignant tumor according to claim 33, wherein said magnetic fine particles are heated to around 43°C and maintained around 43°C.
- 35. (New) The hyperthermia method according to Claim 33, wherein said magnetic fine particles comprise ferrite.

Docket No. F-8198

- 36. (New) The hyperthermia method according to Claim 33, wherein said magnetic fine particles comprise permalloy.
- 37. (New) The hyperthermia method according to claim 33, wherein said magnetic fine particles comprise an antibody which selectively binds to malignant tumor cells.
- 38. (New) The hyperthermia method according to claim 37, wherein said antibody comprises one of a monoclonal antibody (HB4C5) against lung cancer, a monoclonal antibody (17-1A) against large intestine cancer, a monoclonal antibody (H15F2) against breast cancer, and a monoclonal antibody (CH149) against malignant melanoma.
- 39. (New) The hyperthermia method according to claim 5, wherein covering the magnetite with cationic liposome comprises coating the magnetite with a lipid membrane having a positive charge.
- 40. (New) The hyperthermia method according to claim 40, wherein coating the magnetite with a lipid membrane having a positive charge comprises:

washing the magnetite with deionized water to remove excessive ion components;

treating the magnetite with ultrasonic waves to form a magnetite liquor dispersible in water;

adding said magnetite liquor to a phospholipid;

treating the magnetite and phospholipid mixture with ultrasonic waves;

adding physiological saline to said mixture of magnetite and

phospholipid; and

treating the magnetite, phospholipid, and physiological saline mixture with ultrasonic waves.